linjc16/ctgov huggingface dataset:
Effects of Instrument-Applied Spinal Manipulative Therapy on Postureal Control and Autonomic Balance

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of spinal manipulative therapy on autonomic balance and to determine if there exists a relationship between autonomic state and postural control.

Detailed Description
-----------------
Previous studies have demonstrated that sensory and cognitive systems share some common neural substrate. The afferent neural impuleses of mechanoreception (also known as somatosensation) as produced by joint mechanoreceptors and adjacent muscle spindle cells may impact supraspinal centers. Few studies have been done to determine if the afferent impulses generated by spinal manipulative therapy (SMT) can impact the porcessing that occurs at supra-spinal centers. The relationship between postural control and cognition is studies using a dual-tak methodology, a primary (postural) task will often demonstrate degradation with the addition of a secondary, concurrent (cognitive) task. The current study seeks to determine the effects of SMT on postrual control using a dual-task paradigm, while monitoring autonomic state (using Heart Rate Variability analysis) during the course of therapy. It is thought that SMT can improve HRV status, and postural control within a dual-task situation, and that there will be differences in postural control related to a participant's HRV status. Activities of daily living often invole the coupling of a cognitive task with a complex postural task.

Conditions
-----------------
Heart Rate

Intervention / Treatment
-----------------
* Procedure: Instrument-applied spinal manipulative therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adults currently enrolled at Logan College Exclusion Criteria: Lower extremity injury, vestibular disorders

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Instrument-applied spinal manipulative therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effect of Pineapple Juice on the Pharmacokinetics of Celecoxib and Montelukast in Humans

Study Overview
=================
Brief Summary
-----------------
Pineapple (Ananas comosus) is a tropical fruit that is rich in antioxidents, enzymes and vitamins. It is used worldwide due to their anti-inflammatory and analgesic properties. The effect of pineapple Juice on the Pharmacokinetics of celecoxib and montelukast in Humans was studied.

Official Title
-----------------
Effect of Pineapple Juice on the Pharmacokinetics of Celecoxib and Montelukast in Humans

Conditions
-----------------
Food-drug Interaction

Intervention / Treatment
-----------------
* Drug: Celecoxib 100mg
* Drug: Montelukast 10mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subjects (body mass index between 21 to 25 kg/m2). Exclusion Criteria: Smokers. Drug abuse. Abnormal level of kidney or liver functions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Celecoxib<br>Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of celecoxib tablets (100mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study. | Drug: Celecoxib 100mg<br>* Tablets<br>|
| Experimental: Montelukast<br>Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of Montelukast tablets (10mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study. | Drug: Montelukast 10mg<br>* Tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Plasma Concentration [Cmax] |  | 12 weeks | 
| Time to reach plasma peak concentration [Tmax] |  | 12 weeks | 
| Time to reach maximum plasma concentration [Tmax] |  | 12 weeks | 
| The area under the concentration-time curve from zero to infinity (AUC0-∞) |  | 12 weeks | 
| The terminal elimination half-life (t1/2) |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clearance (CLT/F) |  | 12 weeks |
Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?

Study Overview
=================
Brief Summary
-----------------
Treatment strategy of post endoscopic submucosal dissection (ESD) ulcer is not yet conclusive. Rebamipide is a mucosal protective agent widely used in East Asia and has good effect on quality of ulcer healing (QOUH). The investigators will conduct this randomized controlled study to assess the effect of a combination therapy of rebamipide and proton pump inhibitor (PPI) on post ESD ulcer healing.

Official Title
-----------------
Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? : Multicenter, Randomized, and Prospective Study

Conditions
-----------------
Stomach Ulcer

Intervention / Treatment
-----------------
* Drug: Rebamipide
* Drug: pantoprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients underwent ESD for gastric adenoma or cancer Exclusion Criteria: subjects with previous gastric surgery subjects taking aspirin, anticoagulant, or antiplatelet agent subjects having malignancy except gastric cancer pregnant or breast-feeding women

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Pantoprazole<br>controls Pantoprazole 40mg qd for 28days | Drug: pantoprazole<br>* pantoprazole 40mg qd for 28days<br>|
| Active Comparator: Pantoprazole + Rebamipde<br>Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days | Drug: Rebamipide<br>* Rebamipide 100mg Tid for 28days<br>Drug: pantoprazole<br>* pantoprazole 40mg qd for 28days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Healing efficacy of Rebamipide in the treatment of iatrogenic gastric ulcer | Healing efficacy will be assessed by the change of ulcer size. Quality of Ulcer Healing(QOUH) wil be assessed by nodularity in the healed ulcer by two endoscopist. | at 2month after endoscopic submucosal dissection (ESD) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rebamipide, gastric ulcer, healing rate, iatrogenic gastric ulcer after endoscopic submucosal dissection
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML

Study Overview
=================
Brief Summary
-----------------
- To determine the feasibility of fludarabine and cytarabine as continuous infusion plus idarubicin with granulocyte-colony stimulating factor priming for patients with resistant acute myeloid leukemia other than acute promyelocytic leukemia

Detailed Description
-----------------
- The feasibility will be evaluated in terms of toxicities, complete remission rate, duration of complete remission, disease-free survival, and overall survival.

Official Title
-----------------
Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia

Conditions
-----------------
Acute Myeloid Leukemia

Intervention / Treatment
-----------------
* Drug: FLAG+IDA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Failure to achieve CR after initial induction chemotherapy including standard dose cytarabine. Early relapse, occurring after a first CR lasting less than 12 months. Patients with multiple relapses will be included. Written informed consent must be given. 15 and 60 years of age. 2 or less by ECOG performance scale. Exclusion Criteria: acute promyelocytic leukemia pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br> | Drug: FLAG+IDA<br>* Fludarabine, cytarabine, G-CSF<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete remission rate, duration of complete remission, toxicities |  | 06/2008 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression-free survival, overall survival |  | 06/2008 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AML
Statin Therapy in the Treatment of Sepsis

Study Overview
=================
Brief Summary
-----------------
Simvastatin will attenutat IL-6 levels and lead to a more rapid shock reversal than placebo

Official Title
-----------------
Study of Statin Therapy in the Treatment of Sepsis

Conditions
-----------------
Septic Shock

Intervention / Treatment
-----------------
* Drug: Simvastatin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Greater than 18 years old Hypotensive requiring vasopressors Suspected Infection Exclusion Criteria: Pregnant Liver Failure (ALT or AST > 120) Rhabomyolysis (CPK > 3x normal) Comfort care measures status Chronic Liver Disease (Cirrhosis) Use of Cyclosporin, Digoxin, Statins Patients who are unable to take medications by mouth or NGT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Simvastatin 40 mg PO or NGT | Drug: Simvastatin<br>* Simvastatin 40mg PO or NGT<br>* Other names: Zocor;|
| Placebo Comparator: 2<br>Placebo | Drug: Placebo<br>* Corn Starch<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Shock Reversal |  | up to 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory Marker Levels | Change in inflammatory marker levels over time from time zero to time 24 hour. | over 24 hours (time zero and time 24 hours) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
statin, sepsis, septic shock, simvastatin
Lung Ultrasound Score and Weaning Outcome

Study Overview
=================
Brief Summary
-----------------
Objectives: Failure of extubation of patients on mechanical ventilation is one of the common problems in the ICU. Aim of work: To evaluate the validity of lung ultrasound score in prediction of weaning outcomes and post-extubation distress.

Detailed Description
-----------------
Methods: A prospective observational study of 50 patients planned for extubation who passed a spontaneous breathing trial, lung ultrasound score and serum level of NT-PRO BNP were done to all patients at end of spontaneous breathing trial, and all patients were followed after extubation and monitored for oxygenation, re-intubation rate, ICU stay, and ICU mortality.

Official Title
-----------------
Lung Ultrasound Score for Prediction of Weaning Outcome

Conditions
-----------------
Lung Ultrasound Score, Acute Respiratory Failure

Intervention / Treatment
-----------------
* Other: lung ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - 1. Patients age > 18 years 2. Patients intubated and mechanically ventilated for more than 48 hours in the intensive care unit and planned for extubation. Exclusion Criteria: 1. Patients < or =18 years 2. Patients with left ventricular failure 3. Right ventricular failure 4. Pulmonary hypertension 5. Aortic valve disease 6. Hyperthyroidism 7. Tracheostomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: patients eligible for weaning by spontaneous breathing trial<br> | Other: lung ultrasound<br>* Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea<br>|
| Other: non invasive ventilation after weaning<br> | Other: lung ultrasound<br>* Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extubation success | number of participants that do not need for respiratory support neither NIV nor intubation for one week during ICU stay | 48 hours |
Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China

Study Overview
=================
Brief Summary
-----------------
In 1894, Devic first proposed the concept of neuromyelitis optica(NMO). NMO is an inflammatory demyelinating disease that selectively affects the central nervous system of the optic nerve and spinal cord.In 2004, Lennon and other persons found highly specific AQP4（aquaporin 4）antibodies in NMO patients'sera, and further differentiated between NMO and MS, confirming that NMO is an independent disease.At present, NMO has been widely recognized as an idiopathic and severe demyelinating disease of the central nervous system.In 2015, the international NMO diagnostic team developed the diagnostic criteria based on highly specific AQP4 antibodie.Up to now, in China, there is no data on the number of NMOSD patients, the rate of misdiagnosis, the treatment methods, and the prognosis.This study is committed to build China's NMOSD big data platform to provide the basis for diagnosis, treatment and prognosis of the disease.

Official Title
-----------------
Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China

Conditions
-----------------
NMO Spectrum Disorder;Registry Study

Intervention / Treatment
-----------------
* Diagnostic Test: serum AQP4-antibody testing method


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: more than 14 years old Compliance with the diagnostic standard by the NMO International Diagnostic team in 2015 Exclusion Criteria: less than 14 years old NOT Compliance with the diagnostic standard by the NMO International Diagnostic team in 2015

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| positive<br>serum AQP4-antibody is positive | Diagnostic Test: serum AQP4-antibody testing method<br>* there are different methods of testing serum AQP4-antibody<br>|
| negtive<br>serum AQP4-antibody is negtive | Diagnostic Test: serum AQP4-antibody testing method<br>* there are different methods of testing serum AQP4-antibody<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| misdiagnosis rate | misdiagnosis rate of NMOSD | 3 years |
Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of propolis on the treatment of oral candidiasis, more specifically denture stomatitis. Half of participants will receive a standardized-propolis (EPP-AF®) gel formulation while the other half will receive miconazole gel, both for oral use.

Official Title
-----------------
Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People

Conditions
-----------------
Candidiasis, Oral, Stomatitis, Denture

Intervention / Treatment
-----------------
* Other: Propolis
* Drug: Miconazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elderly patients with denture stomatitis Exclusion Criteria: Recent use of anti fungals or antibiotics(2 months or less), dementia

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Propolis<br>Standardized-propolis extract (EPP-AF®) oral gel formulation, 3 times a day, for 14 days | Other: Propolis<br> <br> |
| Active Comparator: Miconazole<br>Miconazole 20mg/g oral gel,3 times a day, for 14 days | Drug: Miconazole<br> <br> * Other names: Daktarin oral gel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Newton Score at 14 days | Clinical assessment of buccal lesions localized at hard palate. The score utilized to measure the intensity of lesions will be Newton classification (I - punctate in the palate; II - extensive smooth reddened appearance; III -extensive reddening with hyperplastic growth) and the outcome will be the reduction of Newton's score comparing day 1 with day 14. | Day 14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of gel acceptability | Application of hedonic scale on day 7 | Day 7 | 
| Assessment of adverse events | Questioning about rise of adverse events on days 7 and 14 | Day 7 and 14 | 
| Anti fungal activity | Colony forming unit count (CFU/mL) on days 1 and 14 | Day 1 and 14 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
propolis, therapeutic, miconazole, denture stomatitis
Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine

Study Overview
=================
Brief Summary
-----------------
The study will be a multi-national, double-blind, randomized, placebo-controlled, parallel group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in approximately 500 patients with chronic angina who remain symptomatic despite daily treatment with the maximum labeled dose of amlodipine (10 mg daily), a calcium channel blocker approved for the treatment of chronic angina. Eligible patients will be randomized to receive ranolazine 1000 mg or placebo twice daily, in addition to a daily dose of 10 mg of amlodipine. Participation in the study will last approximately 3 months.

Official Title
-----------------
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day

Conditions
-----------------
Angina

Intervention / Treatment
-----------------
* Drug: Ranolazine


Participation Criteria
=================
Eligibility Criteria
-----------------
Eligible patients must have a diagnosis of chronic angina, with documented evidence of coronary artery disease or prior myocardial infarction, in addition to other study entry criteria. Prior to entering the study, patients will be required to have had at least two weeks of treatment with amlodipine 10 mg daily, with the discontinuation of all other anti-anginal therapy for the duration of the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ranolazine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Angina, Chest Pain, Coronary Artery Disease, Heart Disease